cytarabine/daunorubicin liposome
/ CSPC Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
June 03, 2025
Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy
(clinicaltrials.gov)
- P2 | N=0 | Withdrawn | Sponsor: Institute of Hematology & Blood Diseases Hospital, China | N=90 ➔ 0 | Initiation date: Feb 2025 ➔ Dec 2025 | Not yet recruiting ➔ Withdrawn
Enrollment change • Trial initiation date • Trial withdrawal • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology
January 13, 2025
Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy
(clinicaltrials.gov)
- P2 | N=90 | Not yet recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital, China
New P2 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology
1 to 2
Of
2
Go to page
1